Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone
    Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone
    • News

  • Aerometrex Expands MetroMap Partner Program as Scalable Model Gains Traction
    Aerometrex Expands MetroMap Partner Program as Scalable Model Gains Traction
    • News

  • Middle East Conflict Starts to Hurt Corporate Earnings Outlooks
    Middle East Conflict Starts to Hurt Corporate Earnings Outlooks
    • News

  • European Lithium and Critical Metals Secure Control of Tanbreez Rare Earth Project
    European Lithium and Critical Metals Secure Control of Tanbreez Rare Earth Project
    • News

  • Harris Technology’s refurbished boom signals FY26 profit inflection
    Harris Technology’s refurbished boom signals FY26 profit inflection
    • News

Little Green Pharma locks in major sales agreement with German cannabis company

  • In News
  • April 19, 2022
  • Jack Cornips
Little Green Pharma locks in major sales agreement with German cannabis company

Australian medical cannabis company Little Green Pharma (ASX: LGP) has reached a major offtake agreement with Demecan to distribute cannabis products across Germany. With the German medical cannabis market estimated to be worth €7.7bn (A$11.2bn) by 2028, this opportunity marks a massive milestone for the Company.

In July 2021, LGP acquired a world-class cultivation site in Denmark to produce 12 tonnes per annum of dried cannabis products. The development fell in line with their plans to ramp up production to meet the future market demand while white-labelling their medicines for supply into the global market. This most recent agreement has allowed the Company to offload a sizable amount of their product and guarantee sales. 

In the agreement, LGP will supply three high-THC flower strains at 450kg per annum to Demecan, with expected annual sales revenue representing €6m (A$9m). The supply agreement is secured for 3-years, where Demecan will have exclusive rights to be the first receiver of products produced by LGP.

Demecan is located in Berlin, Germany and focuses on the cultivation, importation and wholesale of medical cannabis. Having partnered with a European wholesale company, LGP is now positioned with a foot in the door for future growth opportunities around Europe. 

“The agreement gives LGP access to some of the best in-class distribution services in Germany and potentially across Europe as the parties look to roll out these strains across the EU,” said Little Green Pharma CEO, Fleta Soloman.

“This is perfectly aligned with our longstanding strategy to gain market share in Europe, and also marks a significant turning point for the LGP Denmark facility, being the first in what we hope is a suite of high-volume purchase agreements.” 

In their last half-year report, LGP posted a revenue increase of 94% from $3.5m to 7.3m, where $7.2m is solely accounted for by the sales of medical cannabis. This significant increase is from a series of developments where the Company saw its products distributed to Germany, the United Kingdom, France, New Zealand, Brazil, Poland, Lithuania and Denmark. 

For the majority, LGP shares have been tracking down since reaching a high of $1.01 in February 2021, however, since then shares have fallen to a modest $0.45 at the time of writing. 

  • About
  • Latest Posts
Jack Cornips
Trading Desk Assistant at Emerald Financial
Latest posts by Jack Cornips (see all)
  • UNITH delivers eSocial Worker for public health services across 14 countries - December 5, 2023
  • Novatti cashing out of Reckon investment, clears debt to simplify payments business - November 17, 2023
  • Novatti seizes opportunity in Australia’s cashless transition as revenues rise while expenses drop - October 30, 2023
  •  
  •  
  •  
  •  
  • cannabis
  • cannabis healthcare
  • DEMECAN
  • Fleta Soloman
  • Germany
  • lgp
  • lgp asx
  • Little green pharma
  • medical cannabis
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Jack Cornips
Trading Desk Assistant at Emerald Financial
Latest posts by Jack Cornips (see all)
  • UNITH delivers eSocial Worker for public health services across 14 countries - December 5, 2023
  • Novatti cashing out of Reckon investment, clears debt to simplify payments business - November 17, 2023
  • Novatti seizes opportunity in Australia’s cashless transition as revenues rise while expenses drop - October 30, 2023

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Jack Cornips
Trading Desk Assistant at Emerald Financial
Latest posts by Jack Cornips (see all)
  • UNITH delivers eSocial Worker for public health services across 14 countries - December 5, 2023
  • Novatti cashing out of Reckon investment, clears debt to simplify payments business - November 17, 2023
  • Novatti seizes opportunity in Australia’s cashless transition as revenues rise while expenses drop - October 30, 2023
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.